NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
22.49
Dollar change
-0.02
Percentage change
-0.08
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y-12.50% Total Holdings45 Perf Week1.33%
SponsorTema ETF Type Tagsequity Return% 3Y- AUM9.90M Perf Month4.58%
Fund Family Bond Type Tagshealthcare Return% 5Y- NAV/sh Perf Quarter-10.12%
Index- Average Maturity Tags- Return% 10Y 52W High27.39 -17.90% Perf Half Y-16.84%
Index Weighting Commodity Type Tags- Return% SI 52W Low19.86 13.21% Perf YTD-8.08%
Active/Passive Quant Type Tags- Flows% 1M0.00% Volatility0.03% 0.53% Perf Year-4.51%
Dividend TTM0.00 (0.01%) ESG Type Tags- Flows% 3M0.00% ATR (14)0.37 Perf 3Y-
Dividend Ex-DateDec 11, 2024 Dividend Type Sector/Theme Flows% YTD0.00% RSI (14)50.86 Perf 5Y-
Dividend Gr. 3/5Y- - Structure Type Region Flows% 1Y Beta0.76 Perf 10Y-
Expense0.75% Growth/Value SMA200.22% Flows% 3Y Rel Volume0.16 Prev Close22.50
Inverse/Leveraged Market Cap SMA50-0.52% Flows% 5Y Avg Volume0.65K Price22.49
IPOJan 23, 2024 Option/ShortNo / No SMA200-10.00% Trades Volume103 Change-0.08%
Tema Neuroscience And Mental Health ETF seeks to provide long-term growth of capital. Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.